Searchable abstracts of presentations at key conferences in endocrinology

ea0081p657 | Pituitary and Neuroendocrinology | ECE2022

Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatment

C. Arlien-Soborg Mai , Alle Madsen Michael , Dal Jakob , Krusenstjerna-Hafstrom Thomas , Ringgaard Steffen , Skou Nickolaj , Lyng Hogild Morten , Otto Jorgensen Jens

Background: Insulin resistance as part of the metabolic syndrome is associated with ectopic lipid deposition. Growth hormone (GH) status also modulates ectopic lipid accumulation but how this associates with insulin resistance in patients with GH disorders is not well established.Aim: To study body composition, ectopic lipid deposition and insulin sensitivity in acromegaly and adult GH-deficiency before and after treatment.Subjects...

ea0090p432 | Pituitary and Neuroendocrinology | ECE2023

Design of the foresiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly Lonapegsomatropin to Placebo and Daily Somatropin in Adults with Growth Hormone Deficiency (GHD)

Gilis-Januszewska Aleksandra , Fleseriu Maria , Otto Jorgensen Jens , CJ Yuen Kevin , Hoybye Charlotte , Mao Meng , Kang Jennifer , Song Wenjie , Komirenko Allison , Shu Aimee , Beckert Michael

Background: Adult GHD results from insufficient growth hormone (GH) secretion from the anterior pituitary gland and may represent either a continuation of childhood-onset GHD or GHD acquired during adulthood. Clinically, adult GHD is associated with central adiposity, decreased lean muscle mass, increased fat mass, decreased bone mineral density, and reduced quality of life. Current standard of care consists of GH replacement via daily injections. Lonapegsomatropin (SKYTROFA; ...

ea0049gp181 | Pituitary | ECE2017

Targeting either GH or IGF-I levels during somatostatin analogue treatment in patients with acromegaly: A randomized, investigator-initiated multicenter study

Dal Jakob , Klose Marianne , Heck Ansgar , Andersen Marianne , Kistorp Caroline , Nielsen Eigil Husted , Bollerslev Jens , Feldt-Rasmussen Ulla , Jorgensen Jens Otto Lunde

Context: Assessment of disease control in acromegaly depends on GH and IGF-I, but discordant values frequently occur. Further, the role of OGTT-suppressed GH (GHnadir) in somatostatin analogue (SA) treated patients is debated.Objective: To evaluate the effect of targeting either IGF-I or GH during SA treatment.Design: A randomized, investigator-initiated, multicentre trial.Patients and methods: 84 ...

ea0041oc13.2 | Pituitary Clinical | ECE2016

Growth hormone and insulin signalling after acute GH exposure in patients with controlled acromegaly: impact of surgery versus somatostatin analog treatment

Dal Jakob , Lundby Hoyer Katrine , Pedersen Steen B , Magnusson Nils , Bjerrring Peter , Frystyk Jan , Moller Niels , Jessen Niels , Jorgensen Jens Otto L

Background: Somatostatin analogue treatment (SA) is used in acromegaly to suppress GH secretion and tumour growth. In addition, SA also suppresses insulin secretion and may impact on GH signalling in peripheral tissues.Objective: To compare GH and insulin signalling in skeletal muscle and adipose tissue in vivo before and after a single exogenous GH bolus in patients with acromegaly controlled by either surgery alone or by ongoing treatment with a slow-r...

ea0070aep615 | Pituitary and Neuroendocrinology | ECE2020

Cushing’s syndrome negatively affects socio-economic variables many years before the diagnosis: A nationwide registry-based cohort study

Ebbehoj Andreas , Søndergaard Esben , Jepsen Peter , Matilde Lundsgaard Svane Helene , Madsen Morten , Poulsen Per Løgstrup , Jorgensen Jens Otto

Introduction: Cushing’s syndrome (CS) results from prolonged glucocorticoid excess. Both iatrogenic and endogenous CS cause somatic and neuropsychiatric morbidity that do not fully reverse after biochemical disease control. However, the real-world socio-economic consequences for patients and their families are largely unknown.Aim: To determine the impact of CS on work status, income, education, marital status, parenthood, and depression before and ...

ea0070aep748 | Pituitary and Neuroendocrinology | ECE2020

Soluble klotho: A possible predictor of quality of life in acromegaly patients

Coopmans Eva , El-Sayed Nour , Frystyk Jan , Erik Magnusson Nils , Otto Jorgensen Jens , Jan Van der Lely Aart , Janssen Joseph AM , Muhammad Ammar , Neggers Sebastian

Purpose: Although quality of life (QoL) is improved in patients with acromegaly after disease control, QoL correlates only weakly with traditional biomarkers. Our objective is to investigate a potential relation between the new serum biomarker soluble Klotho (sKlotho), GH and insulin-like growth factor 1 (IGF-1) levels and QoL.Methods: In this prospective cohort study, we investigated 54 acromegaly patients biochemically well-controlled on combination tr...

ea0022p617 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Epidemiology of craniopharyngioma in Denmark 1985–2004: a 2% increase in incidence rate per year

Husted Nielsen Eigil , Feldt-Rasmussen Ulla , Poulsgaard Lars , Ostergaard Kristensen Lars , Astrup Jens , Otto Jorgensen Jens , Bjerre Per , Andersen Marianne , Andersen Claus , Jorgensen Jesper , Lindholm Jorgen , Laurberg Peter

Background: Craniopharyngioma may be associated with severe morbidity. Few data exist on incidence rate (IR) and possible changes with time. The epidemiology of craniopharyngioma in Denmark has never been evaluated in detail.Objectives: To review the literature on craniopharyngioma incidence and to study the epidemiology of craniopharyngioma in Denmark during a recent 20-year period.Material and methods: Publications including data...

ea0014p67 | (1) | ECE2007

Intravenous constant ghrelin infusion in healthy young men: sustained cardiovascular effects of supraphysiological ghrelin levels

Vestergaard Esben Thyssen , Andersen Niels Holmark , Hansen Troels Krarup , Rasmussen Lars Melholt , Moller Niels , Sorensen Keld , Sloth Erik , Christiansen Jens Sandahl , Jorgensen Jens Otto Lunde

Objective: The short-term cardiovascular effects of continuous ghrelin infusion in healthy humans remain to be studied.Methods: Fifteen healthy, young and normal-weight men volunteered to participate in a randomized double-blind, placebo-controlled cross-over study. The local ethics committee approved the study. We used a constant infusion of human ghrelin at a rate of 5 pmol/kg body weight per minute for 180 minutes and measured peak left ventricular my...

ea0099p125 | Pituitary and Neuroendocrinology | ECE2024

Consensus and controversies on the diagnosis of GH-deficiency in children and adults - A Delphi survey by the GH research society

C. Arlien-Soborg Mai , Radovick Sally , Cristina da Silva Boguszewski Margaret , Bidlingmaier Martin , Johannsson Gudmundur , R. Hoffman Andrew , Otto Jorgensen Jens

Background: Growth hormone deficiency (GHD) is a rare disorder characterized by pronounced and symptomatic hypo secretion of growth hormone (GH) from the anterior pituitary gland. Biochemical tests are used as part of the diagnosis in both children and adults but controversies remain as regards whom, when, and how to test, and also how to interpret a given biochemical test result.Aim: To map the current clinical practice of GHD diagnosing in children and...

ea0090p19 | Adrenal and Cardiovascular Endocrinology | ECE2023

RESCUE: Effect of supplemental hydrocortisone during stress in glucocorticoid-induced adrenal insufficiency; A study protocol for a multicentre, randomised, double blinded, placebo-controlled clinical trial

Willemoes Borresen Stina , Boggild Hansen Simon , Al-Jorani Hajir , Sofie Bislev Lise , Bue Bjorner Jakob , Brun Boesen Victor , Lehmann Christensen Louise , Fenger Dreyer Anja , Glintborg Dorte , Christian Jensen Richard , Thurmann Jorgensen Nanna , Klose Marianne , Louise Lund Marie , Stankovic Jelena , Tei Randi , Watt Torquil , Otto Lunde Jorgensen Jens , Skovsager Andersen Marianne , Feldt-Rasmussen Ulla

Background: Long-term, low-dose prednisolone treatment (≤5mg/day) is associated with adrenal insufficiency in >33% of patients. Nevertheless, the clinical consequences of glucocorticoid-induced adrenal insufficiency in patients receiving ongoing low-dose glucocorticoid treatment are unknown. Current clinical guidelines do not recommend routine evaluation of adrenal function during low-dose glucocorticoid treatment, and patients are not routinely instructed to increase gl...